Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard TreatmentXi Wang, Fei Xu, Xiwen Bi et al.|JAMA|2020Cited by 229
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trialFei Ma, Binghe Xu, Min Yan et al.|BMJ|2023Cited by 82
Preventing <scp>BRCA</scp>1/<scp>ZBRK</scp>1 repressor complex binding to the <i>GOT2</i> promoter results in accelerated aspartate biosynthesis and promotion of cell proliferationRuoxi Hong, Qimin Zhan, Weimin Zhang et al.|Molecular Oncology|2019Cited by 47
Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancerQinglian Zhai, Shusen Wang, Jiawen Fan et al.|PLoS ONE|2019Cited by 47
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.Zefei Jiang, Hua Yang, Tao Sun et al.|Journal of Clinical Oncology|2022Cited by 36